Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Restructuring Costs (2024)

Amylyx Pharmaceuticals (AMLX) has 1 years of Restructuring Costs data on record, last reported at $22.9 million in Q2 2024.

  • For Q2 2024, Restructuring Costs changed N/A year-over-year to $22.9 million; the TTM value through Sep 2025 reached $22.9 million, changed N/A, while the annual FY2024 figure was $22.9 million, N/A changed from the prior year.
  • Restructuring Costs reached $22.9 million in Q2 2024 per AMLX's latest filing.
  • Across five years, Restructuring Costs topped out at $22.9 million in Q2 2024 and bottomed at $22.9 million in Q2 2024.